Literature DB >> 6540406

Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.

A Reches, H R Wagner, V Jackson-Lewis, E Yablonskaya-Alter, S Fahn.   

Abstract

Refractory response to dopamine (DA) agonists is a common problem in the treatment of Parkinson's disease. In rats with unilateral lesions of the substantia nigra, denervation induced significant increases in striatal 3(H)-spiperone binding sites ipsilateral to the lesion. Chronic treatment with levodopa or with pergolide mesylate significantly decreased the number of 3(H)-spiperone striatal binding sites. Agonist-induced decreases were approximately equivalent in intact and denervated striata and did not appear to be affected by lesions. These results suggest that the poor response to DA agonist in certain parkinsonian patients with chronic drug exposure may be mediated by drug-induced DA receptor down-regulation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540406     DOI: 10.1212/wnl.34.9.1208

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.

Authors:  S Ferre; M Casas; A Cobos; C Garcia; F Jane; J M Grau
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

3.  The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Authors:  P Piccini; D J Brooks; K Korpela; N Pavese; M Karlsson; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

4.  Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Authors:  J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

Authors:  M Guttman; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

6.  Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.

Authors:  L J Porrino; R S Burns; A M Crane; E Palombo; I J Kopin; L Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.